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Recent Changes to the Prescribing of
Schedule-II Controlled Substances
By: Brie Dunn, PharmD Candidate
As prescribing practices change
with regard to pain and psychiatric management and new or generic medications come to market, the quantity and availability
of controlled substances has dramatically increased. Many believe that the diversion and
abuse of prescription medications is a significant public
health problem. Collectively, as
health care providers, it is our
responsibility to help prevent
diversion and identity incidents
of abuse or addiction when they
arise.
Schedule II (C-II) controlled
substances include commonly
prescribed medications such as
codeine, methylphenidate, morphine and oxycodone among
many others. Required findings
for a drug to be placed in this
category are that
(a) the drug or other substance
has a high potential for
abuse,
(b) the drug or other substance
has a currently accepted
medical use in treatments in
the United States or a currently accepted medical use
with severe restrictions and
lastly

(c) abuse of the drug or other substances may lead to severe
psychological or physical dependence.
A current list of C-II medicaitons
is available from the Drug Enforcement Agency (DEA) at
www.deadiversion.usdoj.gov/schedules/
listby_sched/sched2.htm.1

Historically, physicians had the
ability to post-date C-II prescriptions. Physicians could issue multiple prescriptions for a specific
substance by providing written
instructions on when the prescriptions were to be filled. However,
in 2004, DEA saw this privilege
as being similar to refills and decided to amend the rule. Therefore, under federal law, refilling of
C-II medications was prohibited.
By prohibiting prescribers from
issuing multiple prescriptions at
one time, patients’ access to necessary medications was significantly impacted. Under the old
amendment, patients were required to visit their physician for
each new prescription order, regardless of length and maintenance of treatment.
In September 2006, DEA published a Notice in the Federal
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Table 1: 2007 Changes to the Code of Federal Regulations
§ 1306.12 Refilling prescriptions; issuance of multiple prescriptions3
An individual practitioner may issue multiple prescriptions authorizing the patient to receive a total of up to a 90-day supply
of a Schedule II controlled substance provided the following conditions are met:
i. Each separate prescription is issued for a legitimate medical purpose by an individual practitioner acting in the usual
course of professional practice
ii. The individual practitioner provides written instructions on each prescription (other than the first prescription, if the
prescribing practitioner intends for that prescription to be filled immediately) indicating the earliest date on which a
pharmacy may fill each prescription;
iii. The individual practitioner concludes that providing the patient with multiple prescriptions in this manner does not create an undue risk of diversion or abuse;
iv. The issuance of multiple prescriptions as described in this section is permissible under the applicable state laws; and
v. The individual practitioner complies fully with all other applicable requirements under the Act and these regulations as
well as any additional requirements under state law.
Nothing in this paragraph (above) shall be strued as mandating or encouraging individual practitioners to issue multiple prescriptions or to see their patients only once every 90 days when prescribing Schedule II controlled substances. Rather, individual practitioners must determine on their own, based on sound medical judgments.
§ 1306.14 Labeling of substances and filling of prescriptions3
Where a prescription that has been prepared in accordance with section 1306.12(b) contains instructions from the prescribing
practitioner indicating that the prescription shall not be filled until a certain date; no pharmacist may fill the prescription before that date.

Register proposing the multiple
prescriptions amendment and asking for comments. Of the 264
comments received, the vast majority were supportive of its adoption. Supporters included a variety of pharmacy, medical and
nursing interest groups; medical
professionals; state boards of
pharmacy; and patients. Many
say it will reduce the hardship of
making costly and sometimes long
trips for monthly visits to the physician for patients with chronic
pain. It may also help parents and
their children reduce the number
of days missed of school or work
due to doctor appointments.
Those opposed either opposed the
entire admendment or suggested
modifications. Concerns were
raised about the potential increase
in drug diversion and abuse, decline in close patient monitoring,
and difficulties with reimbursement for a 90-day supply.2
On November 19, 2007, DEA
published a Final Rule in the Fed-

eral Register addressing the Issuance of Multiple Prescriptions
for Schedule II Controlled Substances as a potential means to
curtail drug diversion and abuse.
This rule, which became effective December 19, 2007, makes

The

it possible for prescribers to write
multiple prescriptions, to be filled
sequentially, for the same C-II
controlled substances.
Although the refilling of C-II
drugs is still prohibited, this new

MED•U•WAY
To Care For Patients
*** An MUSC Lecture Series***

The next MED•U•WAY
Conference will focus on
smoking cessation.
The program will be held on
Thursday, May 15, 2008, at
12:00 PM, in 2 West
Amphitheater.
The featured speakers will
include Bob Mallin, MD,
Department of Family Medicine;
Sarah Shrader, PharmD,

Assistant Professor, South
Carolina College of Pharmacy MUSC Campus; and
Reid
Marmillion, Respiratory Therapy.
Phyicians, nurses, and pharmacists
attending the conference will
receive 1 credit hour of continuing
education.
MED•U•WAY is sponsored by
the Pharmacy and Therapeutics
Committee. Lunch is provided.
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regulation allows patients to have
a 90-day supply of the drug. Specifically, Title 21 of the Code of
Federal Regulations was amended
(see Table 1).3
The new regulation does not affect
current state laws and regulations.
In South Carolina, prescriptions
for C-II substances are still limited
to a 31-day supply; yet, the new
federal amendment allows for patients to see their physician every
90 days for a new prescription, if
approved by the physician.
Physicians must use their medical
judgment to determine whether it
is appropriate to issue multiple
prescriptions and how often to
schedule each patient’s visit. Under no circumstances shall a C-II
prescription be dispensed more
than 60 days after the date of issue.
These two laws are different from
the federal law; however, more
stringent state laws overrule the
federal stipulation. DEA and federal law do not require that a C-II
prescription be filled within a certain time period, nor do they specify a specific limit on quantity au-
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Table 2: Requirements for Issuing a Prescription in South Carolina
In South Carolina, prescriptions for controlled substances must
be written with indelible ink or typewriter and include:1,4
Date of issue
Full name and address of the patient
Drug name, strength, dosage form, quantity prescribed and
directions for administration
Prescriber name, address and DEA registration number
(can NOT be pre-printed)
Signature of the prescriber
(can NOT be electronic)
thorized on the prescription.
When issuing a prescription in
South Carolina there are several
requirements outlined by the
Board of Pharmacy (Table 2).
There is one loop hole that may
cause significant headache for
patients, pharmacists and prescribers. It is important to make
sure that the prescriptions are
dated appropriately as the 60day expiration limit is important
to remind patients. If the patient
tries to fill the last prescription
after the 60 days from the time it
was written, the prescription will
not be valid. This can be best
explained by the examples in
Figure 2.

A representative from the South
Carolina DHEC, stated that this
law will potentially be changed in
the upcoming year to allow for a
90-day supply of C-II medications, as allowed by the federal
law. A summary of the regulations as currently written is listed
below for reference (Figure 1).
The new law demonstrates the recent increase in communication
between health care providers and
law enforcement officials. It also
gives prescribers more freedom,
while still appropriately regulating
the medications in question.4
References available upon request

Figure 1: Summary of Regulations for Schedule II Controlled Substances1,4
▪ Each prescription must be issued for a legitimate medical purpose by a practitioner acting in the usual
course of professional practice
▪ Each prescription must be written on a separate prescription blank with the actual date written of when
the prescription was written by the physician
▪ The practitioner must provide written instructions on each prescription (other than the first prescription to
be filled immediately) indicating the earliest date a pharmacy may fill each prescription
▪ The practitioner must determine that providing the patient with multiple prescriptions does not create an
undue risk of diversion or abuse
▪ Postdating is not allowed
▪ Pharmacists are NOT allowed to change the “do not fill before” date under ANY circumstances – this
includes verbal authorization from the prescriber
▪ The practitioner must comply fully with all other applicable requirements under state and federal law
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Figure 1. Examples of Issues that may Occur with the New Prescribing Laws
Example 1: Dr. Smith writes a prescription for Adderall® XR for John Doe on January 1, 2008. The family requests a 3-month supply since they have a hectic schedule and find it difficult to report to the office monthly for a new prescription. JD has been stabilized on this medication for several years and Dr. Smith feels that this is an appropriate request. Two additional prescriptions are
written for Adderall® XR and dated with today’s date, January 1, 2008. On one prescription, Dr. Smith writes “to be filled on February 1, 2008” and on the third, “to be filled on March 1, 2008.” JD takes his prescription to the pharmacy to be filled immediately
and receives a 31 day supply. The following month, 31 days later he returns to the pharmacy to have the second prescription filled.
The following month on March 1, he returns again expecting to receive his third and final supply of medication; however, to his surprise, the prescription could not be filled because it was older than 60 days (Recap: Dated January 1, 2008 to be filled March 1,
2008). Angry, he phones his physician and complains that he thought he had 3 months worth of prescriptions, not 2!
Example 2: Dr. Smith writes a prescription for oxycodone for Jane Doe on January 1, 2008. She has had chronic pain for several
years and is well controlled on her current opioid dose. Traveling to the office monthly is a significant burden on JD as she lives
nearly an hour away. Dr. Smith feels that it is appropriate to schedule her next visit for 90 days and subsequently writes her 2 additional prescriptions for oxycodone. Each is dated with today’s date, January 1, 2008 and specific instructions are written on when to
fill (February 1 and March 1 as in above example). JD left the office and went to get her prescription filled. Although JD still has a
couple of pills left, she is leaving town for the weekend and visits the pharmacy 2 days early. The pharmacist agrees to fill the prescription because according to state law a controlled prescription can be filled up to 48 hours early once during its lifespan. JD again
returns in a month to fill the third and final prescription. Contrastingly to John, Jane is able to fill her third prescription and gets the
full 90-day supply because the third prescription was not older than 60 days.

Did You Know…Prescription Law Updates
By: Kelly Crowley, RPh
Ashley River Tower Outpatient Pharmacy
Pharmacy laws change many times throughout the year. Rather than assuming what changes may have occurred, please refer to this column to get the current information. The information is verified with the Board of
Pharmacy and Drug Enforcement Administration (DEA). Below are some of the most recent changes.
1. A practitioner can electronically transmit prescriptions if the following conditions are met:
− Valid practitioner-patient relationship must exist
− Prescription must identify the transmitter's phone #, time and date of transmission, pharmacy
intended to receive
− All other requirements of a prescription (ie, patient name, date, medication, quantity, directions for use,
signature, refills)
* Practice Partner does not yet have the capability to transfer electronically; however, this functionality is being developed..

2. Practitioners can fax prescriptions for controlled substances to pharmacies as long as the signature is
"signed", not computer generated. The prescription must include the name and address of practitioner, an
office phone number, time and date of transmission, name of pharmacy intended to receive, as well as all
other required info (ie, patient name, date, medication, quantity, directions for use, refills, DEA number).
3. Schedule II controlled substances can be written for 31 day supply and are valid for 90 days from
date issued.
4. Schedule III, IV, V can be written for up to a 90 day supply.
− Prescription is valid for 6 months from date of issue.
5. DEA amended its regulations to allow practitioners to provide individual patients with multiple prescriptions, to be filled sequentially, for the same schedule II substance [see previous article on pages 1 – 3]. It
did not address the "do not fill until ...." language. As of now, there is nothing in the Control Substance Act
or DEA that says the prescriber cannot write that on an prescription.
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Duloxetine (Cymbalta®): Appropriate Monitoring for Liver Toxicity
By: Cory Grzesik, PharmD, Lynette Lemacks, PharmD, and Ashley Lewis, PharmD
MUSC Medical Center and College of Pharmacy Residency Program
Duloxetine (Cymbalta®) is a dual
serotonin and norepinephine reuptake inhibitor (SNRI) indicated for
the treatment of major depressive
disorder (MDD) and generalized
anxiety disorder (GAD).1,2 Additionally, it is indicated for the
treatment of pain associated with
diabetic peripheral neuropathy, as
serotonin and norepinephrine are
involved in pain modulation via
descending inhibitory pathways in
the brain and spinal cord.3,4

due to the risk for irritation of
pre-existing liver disease or the
possibility for liver damage
when alcohol and duloxetine are
used concurrently, duloxetine
should not be given to patients
consuming substantial amounts
of alcohol or who exhibit evidence of chronic liver disease.1,2
Heavy drinking is defined by the
manufacturer as 5 or more drinks
per day for men and 4 or more
drinks per day for women.1

Duloxetine is typically administred once daily up to 60 mg/day.
It undergoes extensive metabolism
in the liver and may potentially
lead to elevated serum transaminase concentrations; therefore,
liver function should be monitored.1,2
The product labeling describes
post-marketing reports of transaminase elevations greater than 20
times the upper limit of normal
with or without jaundice in patients taking duloxetine.1 Hepatitis
with abdominal pain and cholestatic jaundice have also been reported.1,5 According to the product
labeling, dose response relationships for aspartate aminotransferase (AST) elevations greater
than 5 times the upper limit of
normal and alanine transaminase
(ALT) elevations greater than 3
times the upper limit of normal
have been observed in patients.1
In addition, patients with chronic
liver disease or cirrhosis have experienced elevated bilirubin, alkaline phosphate and transaminases
while on duloxetine.1,2 Therefore,

Due to this risk, it is important to
monitor liver function in patients
receiving duloxetine therapy. A
medication use evaluation was
conducted to assess the incidence of hepatotoxicity in patients receiving duloxetine. For
the purpose of the review, hepatotoxicity was defined as greater
than 3 times the upper limit of
normal of AST and/or ALT. Additionally, the review evaluated
the indication for use of duloxetine and whether or not appropriate monitoring of liver function
tests were performed.
The investigators performed a
retrospective chart review of 300
patients that received duloxetine
while hospitalized from August

2006 to August 2007. Patients
were included if they were at least
18 years of age and received at
least 1 dose of duloxetine. Nine
patients were excluded due to age
< 18 years of age. Liver function
was assessed by reviewing AST,
ALT, alkaline phosphatase (ALK
PHOS), total bilirubin (bili-T),
and direct bilirubin (bili-D). In
addition, percent carbohydrate
deficient transferrin (% CDT) was
used as a marker for alcohol intake when available.
During or within 3 months of hospitalization, 71% patients had
liver function monitoring. At least
1 laboratory value associated with
liver function was elevated in 37%
patients. The mean laboratory values and percentage of elevated
values are listed in Table 1. According to the definition used in
this review, approximately 3% of
patients evaluated met the predefined criteria for hepatotoxicity.
Depression (58%) was the most
commonly cited indication for use
of duloxetine followed by neuropathic pain (25%) and anxiety
(9%). Out of these patients, 48
were taking duloxetine for dual
indications and one subject had 3
indications listed. The majority
of patients (88%) were receiving
duloxetine prior to hospital admission.
A total of 197 (67%) patients were
on concomitant medications that
may negatively affect liver function. The most common medication was acetaminophen (n=161,
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Table 1. Liver Function Laboratory Test Results
Laboratory
Test

Mean Value
[range]

Normal
Value Range

Total
Elevated
Values

Total
Number
Collected

AST (IU/L)

35
[12 to 227]

8 to 38

48
(23%)

208
(71%)

ALT (IU/L)

35
[7 to 288]

7 to 45

39
(19%)

208
(71%)

ALK PHOS
(IU/L)

113
[4.80 to 890]

25 to 100

84
(40%)

208
(71%)

Bili-T (mg/dL)

1.01
[0.05 to 26]

0.2 to 1.3

15
(7%)

205
(70%)

Bili-D (mg/dL)

0.20
[0.01 to 1.1]

0.1 to 0.3

8
(13%)

64
(22%)

% CDT

2.8
[1.5 to 13]

< 2.6

5
(31%)

16
(6%)

55%), followed by the HMG CoA
reductase inhibitors (n=79, 27%)
patients. Alcohol abuse or dependence was reported in 38
(13%) patients, cirrhosis was reported in 1 patient (0.003%),
hepatitis was reported in 9 patients
(0.03%), and hepatocellular cancer was reported in 4 patients
(0.01%). Figure 1 represents the
number of patients with elevated
liver parameters within each concomitant disease state. Additionally, not all patients who reported
concomitant disease states received liver function monitoring
during hospitalization even though
these patient populations warrant
liver function monitoring.
Duloxetine does not pose significant risk for hepatotoxicity when
used and monitored appropriately.
Concerns for hepatic elevations
are valid. Currently, there are no
manufacturer recommendations as
to the appropriate frequency or
duration of hepatic monitoring. It
is recommended to obtain a liver
function panel on admission to

determine if therapy should be
continued. Additionally, patients
should be monitored throughout
therapy based on the practitioner’s clinical assessment. It is
responsibility of the treating clinician to fully inform their patient about the risk of liver damage with the use of duloxetine,
especially in patients with existing hepatic diseases or heavy

alcohol consumption and patients
receiving other medications that
may affect liver function. It was
beyond the scope of this analysis
to determine causality of elevations, but appropriate hepatic
monitoring may decrease the use
to duloxetine in inappropriate patients.
Duloxetine has been denied for
addition to the formulary in previous years due to the potential for
liver toxicity. However, duloxetine remains a highly used nonformulary medication. Based on the
MUE results, the Pharmacy and
Therapeutics Committee voted to
add duloxetine to the MUSC-MC
Formulary of Accepted Drugs.
Information will be sent via Email, inservices will be provided,
and flyers will be posted. The formulary effective date will be May
15, 2008.
The authors would like to acknowledge Amy VandenBerg, PharmD, and Kelli Garrison, PharmD for
their assistance with this project and manuscript.
References available upon request

Figure 1. Concomitant Disease States Related to Liver Function
Test Elevations
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FORMULARY UPDATE FOR MARCH 2008
The Pharmacy and Therapeutics
Committee recently approved the
actions listed below. The formulary effective date was April 15,
2008.
Additions:
Lubiprostone (Amitiza®) is approved for the treatment of
chronic idiopathic constipation in
adults. Currently, it is the only
agent FDA approved for this indication. Recent trials have demonstrated efficacy with a dose of
24 micrograms given twice a day.
Although nausea is a common
side effect, it is often mild and can
be minimized by giving lubiprostone with food. Based on acquisition costs, a one month supply of
lubiprostone is significantly more
than other formulary alternatives;
however, it would be a secondor third-line medication for constipation after other measures had
failed.
24-microgram capsule

Symbicort® is approved for the
long-term maintenance of asthma
in patients 12 years of age and
older.
Symbicort®
contains
budesonide, an anti-inflammatory
corticosteroid, and formoterol, a
long-acting selective beta2 adrenergic agonist, which acts locally
as a bronchodilator. There are no
head-to-head trials between Symbicort® and Advair® nor is there
information to support a direct
conversion of one inhaler to the
other. The acquisition cost of
Symbicort® is comparable to that
of lower initial doses of Advair®
and may have potential price advantages over Advair® when in-

creased strengths are used. The
Committee did not want to remove Advair® from the formulary since it is more widely used
and known by patients and staff,
so Symbicort® was added for
those patients who are admitted
to the hospital on Symbicort® as
an outpatient.
80/4.5 micrograms (60 doses) and
160/4.5 micrograms (60 doses)

Duloxetine (Cymbalta®) is a
dual serontonin and norepinephrine reuptake inhibitor indicated
for the treatment of major depressive disorder and generalized anxiety disorder. It is also
indicated for the treatment of
pain associated with peripheral
neuropathy. Abnormal liver
function tests (LFTs) may reported in patients taking duloxetine. Based on the findings of a
recent medication use evaluation, 30% of the patients prescribed duloxetine did not receive appropriate monitoring.
Approximately 3% of the patients in the study met the predefined criteria for hepatotoxicity.
Duloxetine has been denied for
addition to the formulary in previous years due to the potential
for liver toxicity. However, it
was decided to add duloxetine to
the formulary after an appropriate time for education of house
staff regarding the need for
monitoring LFTs in patients receiving duloxetine. The formulary effective date will be
May 15, 2008
20-, 30-, and 60-mg capsules

Change in Restriction:
The restriction for ertapenem

(Invanz®) has been extended to
include surgical prophylaxis in
patients undergoing colon-specific
surgery as per the SCIP guidelines. This change will be reflected on the ertapenem physician order form.
Line Extensions:
▪ Lanolin cream (Medela Tender Care®)
[2 oz tube]
▪ Pantoprazole oral suspension
(Protonix®) [40-mg suspension packet]

Deletions:
▪ Lanolin cream (Lansinoh®) [2 oz tube]
▪ Colchicine [0.5-mg/mL injection]
▪ Dinoprostone (Prostin E2) [20-mg
vaginal suppository]

▪ Ergotamine/caffeine (Cafergot®)
▪
▪
▪
▪
▪
▪
▪
▪
▪
▪
▪
▪
▪
▪

[2-mg/100-mg suppository]
Chlorambucil (Leukeran®)
[2-mg tablet]
Chloroquine (Aralen®) [500-mg tablet]
Furazolidone (Furoxone®)
[100-mg tablet]
Haloperidol (Haldol®) [20-mg tablet]
Methyltestosterone (Android®)
[10-mg capsule]
Mifepristone (Mifeprex®)
[200-mg tablet]
Neostigmine (Prostigmin®)
[15-mg tablet]
Propantheline (Pro-Banthine®)
[7.5-mg tablet]
Pyridostigmine (Mestinon Timespan®)
[180-mg tablet]
Sodium fluoride (Luride®) [1-mg
chew tablet]
Sotalol (Betapace®) [240-mg tablet]
Thyroid desiccated (Armour Thyroid®)
[15-, 120-, and 180-mg tablets]
Tocainide (Tonocard®) [400-mg tablet]
Tolcapone (Tasmar®) [100- and 200mg tablets]

